Prostate cancer: cardiovascular mortality and androgen deprivation.
Every treatment has unintended adverse effects, and androgen deprivation therapy (ADT) for prostate cancer is no exception. A flurry of reports has implicated ADT in increasing cardiovascular risk and mortality. In this regard, the 2009 study by Efstathiou and colleagues is a notable exception.